Abstracts tagged "rheumatoid arthritis (RA) and treatment"

Abstract Number: 3184 • 2015 ACR/ARHP Annual Meeting
Is Treat-to-Target Really Working? a Longitudinal Analysis in Biodam
Sofia Ramiro¹, Robert B.M. Landewé², Désirée van der Heijde¹, Oliver FitzGerald³, Mikkel Østergaard^4,5, Joanne Homik⁶, Ori Elkayam⁷, J Carter Thorne⁸, Margaret Larche⁹, Gianfranco Ferraccioli¹⁰, Marina Backhaus¹¹, Gilles Boire¹², Bernard Combe¹³, Thierry Schaeverbeke¹⁴, Alain Saraux¹⁵, Maxime Dougados¹⁶, Silvano Adami¹⁷, Marcello Govoni¹⁸, Luigi Sinigaglia¹⁹, Alain G. Cantagrel²⁰, Cornelia F. Allaart¹, Cheryl Barnabe²¹, Clifton O. Bingham III²², Paul P. Tak²³, Dirkjan van Schaardenburg²⁴, Hilde Berner Hammer²⁵, Rana Dadashova²⁶, Edna Hutchings²⁶, Joel Paschke²⁶ and Walter Maksymowych²⁷, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ³Rheumatology, St Vincent's University Hospital, Dublin, Ireland, ⁴Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ⁵Rigshospitalet-Glostrup, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, Glostrup, Denmark, ⁶Rheumatology, University of Alberta, Edmonton, AB, Canada, ⁷Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁸University of Toronto, Toronto, ON, Canada, ⁹Rheumatology, McMaster University, Hamilton, ON, Canada, ¹⁰Rheumatology and Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy, ¹¹Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, ¹²Department of Medicine/Division of Rheumatology, University of Sherbrooke, Sherbrooke, QC, Canada, ¹³Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ¹⁴Rheumatology, Pellegrin University Hospital, Bordeaux, France, ¹⁵Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ¹⁶Cochin Hospital, Paris Descartes University, Paris, France, ¹⁷University of Verona, Verona, Italy, ¹⁸University of Ferrara, Ferrara, Italy, ¹⁹Department of Rheumatology, Gaetano Pini Institute, Milan, Italy, ²⁰Dept of Rheumatology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ²¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²²Rheumatology, Johns Hopkins University, Baltimore, MD, ²³Division of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²⁴Rheumatology, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ²⁵Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²⁶CaRE Arthritis, Edmonton, AB, Canada, ²⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: A Treat-to-Target approach (T2T), treating patients with RA towards a target, either remission or low disease activity (T2T-REM or T2T-LDA), is nowadays recommended. However…
Abstract Number: 1041 • 2015 ACR/ARHP Annual Meeting
Methotrexate Monotherapy and Methotrexate Combination Therapy with Traditional and Biologic Dmards for Rheumatoid Arthritis: A Cochrane Systematic Review and Network Meta-Analysis
Glen S. Hazlewood^1,2, Cheryl Barnabe³, George A. Tomlinson⁴, Deborah Marshall⁵, Daniel Devoe⁵ and Claire Bombardier⁶, ¹Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶18 Strathearn Blvd, University of Toronto, Toronto, ON, Canada
Background/Purpose: To compare methotrexate based disease-modifying anti-rheumatic drug (DMARD) treatments for rheumatoid arthritis in patients naïve to or after an inadequate response (IR) to methotrexate. …
Abstract Number: 3185 • 2015 ACR/ARHP Annual Meeting
A Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach in the Clinical Care of Rheumatoid Arthritis Patients in the United States
Leslie Harrold^1,2, George W. Reed^1,2, J. Timothy Harrington³, Christine J. Barr¹, Katherine C. Saunders¹, Allan Gibofsky⁴, Eric M. Ruderman⁵, Tmirah Haselkorn⁶, Jeffrey D. Greenberg^1,7, Ani John⁶ and Joel M. Kremer⁸, ¹Corrona, LLC, Southborough, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Joiner Associates, LLC, Madison, WI, ⁴Hospital for Special Surgery, New York, NY, ⁵Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Genentech, Inc, South San Francisco, CA, ⁷NYU School of Medicine, New York, NY, ⁸Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: We report the results of a cluster-randomized behavioral intervention trial designed to assess the impact of implementing a treat-to-target (T2T) approach vs usual care…
Abstract Number: 1048 • 2015 ACR/ARHP Annual Meeting
Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study
R Westhovens¹, Rieke Alten², Dace Pavlova³, Favio Enríquez-Sosa⁴, Minodora Mazur⁵, Maria Greenwald⁶, Annegret Van der Aa⁷, Frédéric Vanhoutte⁷, Chantal Tasset⁷ and Pille Harrison⁷, ¹Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, KU Leuven, Leuven, Belgium, ²Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ³LTD M & M Centrs, Carnikava, Latvia, ⁴CLINSTILE, S.A. DE C.V, Mexico, Mexico, ⁵IMSP Institul de Cardiologie, Chisinau, Moldova, ⁶Desert Medical Advances, Palm Desert, CA, ⁷Galapagos NV, Mechelen, Belgium
Background/Purpose: Filgotinib (GLPG0634) is a novel oral, potent and selective JAK1 inhibitor that has previously demonstrated efficacy in combination with methotrexate (MTX) in treating rheumatoid…
Abstract Number: 2517 • 2014 ACR/ARHP Annual Meeting
Long-Term Clinical, Structural, and Functional Consequences of Not Adopting Treatment in MTX Suboptimal Responders
Josef Smolen¹, Ronald F. van Vollenhoven², Stefan Florentinus³, Yijie Zhou⁴, Benoit Guerette⁴ and Arthur Kavanaugh⁵, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²The Karolinska Institute, Stockholm, Sweden, ³AbbVie, Rungis, France, ⁴AbbVie, Inc., North Chicago, IL, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Methotrexate (MTX) is used as first line therapy for treatment of rheumatoid arthritis (RA). Current recommendations state that therapy should be adjusted if patients…
Abstract Number: 946 • 2014 ACR/ARHP Annual Meeting
Phase 1 Study of Immunotherapy Using Autoantigen-Loaded Dendritic Cells in Patients with Anti-Citrullinated Peptide Antigen Positive Rheumatoid Arthritis
Young Bin Joo¹, Jun-Eui Park², Chan-Bum Choi³, Jeongim Choi¹, Jin-ah Jang², Minkyu Heo², Hak-yeop Kim², Hye-Soon Lee⁴, Yong-Soo Bae⁵ and Sang-Cheol Bae¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²JW CreaGene Research Institute, JWCreaGene Inc., Seongnam-si, South Korea, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁵3Department of Biological Science, Sungkyunkwan University, Suwon, South Korea
Background/Purpose To date, no dendritic cell (DC) immunotherapy has been shown to give a benefit in patients with rheumatoid arthritis (RA). In this prospective phase…
Abstract Number: 2498 • 2014 ACR/ARHP Annual Meeting
Characteristics of Responding Versus Non-Responding Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate
Josef Smolen¹, David Collier², Annette Szumski³, Heather Jones⁴ and Lisa Marshall⁵, ¹PsAID taskforce, EULAR, Zurich, Switzerland, ²Amgen, Inc., Thousand Oaks, CA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ⁵Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA
Background/Purpose While synthetic or biologic disease-modifying antirheumatic drugs (DMARDs) are often effective, treatment with such agents does not adequately control disease activity in all patients.…
Abstract Number: 398 • 2014 ACR/ARHP Annual Meeting
Anti-Rheumatic Therapy Decreases Syndecan-1 Shedding in Rheumatoid Arthritis (RA)
Ivana Hollan¹, Gunnbjørg Hjeltnes², Torstein Lyberg³, Stefan Agewall³, Allan Wiik⁴, Knut Mikkelsen⁵, Øystein T. Førre⁶, Tram T. Vuong³ and Svein O. Kolset³, ¹Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ²Medicine, Innlandet Hospital Trust, Lillehammer, Norway, ³University of Oslo, Oslo, Norway, ⁴Clinical Biochem/Immunology, Statens Serum Institute, Copenhagen S, Denmark, ⁵Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁶Oslo University Hospital, Oslo, Norway
Background/Purpose Intact glycocalyx is of importance for healthy endothelial function. Changes in the endothelial glycocalyx, characterized by increased levels of circulating syndecan-1, might be related…
Abstract Number: 2492 • 2014 ACR/ARHP Annual Meeting
Does Body Mass Index Impact Long-Term Retention with Abatacept in Patients with RA Who Have Received at Least One Prior Biologic Agent? 2-Year Results from a Real-World, International, Prospective Study
H Nüßlein¹, R Alten², M Galeazzi³, HM Lorenz⁴, MT Nurmohamed⁵, WG Bensen⁶, Gerd Burmester⁷, H-H Peter⁸, P Peichl⁹, K Pavelka¹⁰, M Chartier¹¹, C Poncet¹², C Rauch¹³ and M Le Bars¹⁴, ¹Internistische Schwerpunktpraxis, Nürnberg, Germany, ²Schlosspark-Klinik University Medicine, Berlin, Germany, ³University of Siena, Siena, Italy, ⁴University Hospital, Heidelberg, Germany, ⁵VU Univ Medical Center/Jan van Breeman Research Institute, Amsterdam, Netherlands, ⁶St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ⁷Charité-Universitätsmedizin, Berlin, Germany, ⁸University of Freiburg, Freiburg, Germany, ⁹Evangelisches Krankenhaus, Vienna, Austria, ¹⁰Institute of Rheumatology, Charles University, Prague, Czech Republic, ¹¹Chiltern International, Neuilly, France, ¹²Docs International, Nanterre, France, ¹³Bristol-Myers Squibb, Munich, Germany, ¹⁴Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: In RA, reduced efficacy with anti-TNF therapy1 and dose escalation2 have been reported for obese patients (pts) compared with non-obese pts. Clinical trials have…
Abstract Number: 350 • 2014 ACR/ARHP Annual Meeting
Rho-Associated Protein Kinase (ROCK) Activity Is Elevated in Rheumatoid Arthritis (RA) Patients and May be Responsive to RA Therapies
Reena Khianey¹, Cristina Rozo², Sanjay Gupta³, Vivian P. Bykerk¹, Susan M. Goodman¹ and Alessandra B. Pernis⁴, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²535 East 70th Street, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Research, Hospital for Special Surgery, New York, NY
Background/Purpose: Rho-associated protein kinases (ROCKs) regulate cytoskeletal reorganization and gene expression through protein phosphorylation, and are implicated in the pathogenesis of a wide range of…
Abstract Number: 2441 • 2014 ACR/ARHP Annual Meeting
Prevalence and Determinants of Treatment Adherence Among Patients with Rheumatoid Arthritis
Maria Celeste Orozco¹, Maria Florencia Marengo², Christian A. Waimann², Ana Inés Marcos³, Amelia Granel³, Sofia Velez⁴, Federico Zazzetti⁵, Juan C. Barreira⁶, Paula Kohan⁷, Oscar L. Rillo⁸, María Victoria Collado⁹, Graciela Gómez¹⁰, Ricardo V. Juárez¹¹, Veronica Lencina¹², Andrea D'Orazio¹³, Gustavo Rodriguez Gil¹³, Mariana Salcedo¹⁴ and Gustavo Citera¹⁵, ¹Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Rheumatology, Hospital San Roque de Gonnet, La Plata, La Plata, Argentina, ⁴Rheumatology, Hospital Britanico, Buenos Aires, Argentina, ⁵Hospital Britanico, Buenos Aires, Argentina, ⁶Rheumatology, British Hospital, Buenos Aires, Argentina, ⁷rheumatology, Hospital Gral. de agudos Dr. E. Tornú, Buenos Aires, Argentina, ⁸Rheumatology Unit, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ⁹Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ¹⁰Diaz Colodrero 2537 8° A, Insituto de Investigaciones Medicas de la UBA, Capital Federal, Argentina, ¹¹Rheumatology Section, Hospital Señor del Milagro, Salta, Argentina, ¹²Rheumatology section, Hospital Señor del Milagro, Salta, Argentina, ¹³rheumatology, Hospital Municipal de agudos Dr. Leonidas Lucero, Bahía Blanca, Argentina, ¹⁴Consultorio Privado, San Nicolás, Argentina, ¹⁵Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose : Treatment adherence is a crucial part of successfully managing rheumatic diseases such as Rheumatoid Arthritis (RA). Low adherence to treatment has been related…
Abstract Number: 322 • 2014 ACR/ARHP Annual Meeting
Superior Therapeutic Efficacy of a Novel Oral Small Molecule Retinoic Acid Receptor-Related Orphan Receptor Gamma T [Rorgt] Inverse Agonist Inv-17: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis
Anderson Gaweco^1,2, Samantha Palmer¹, Rambon Shamilov¹, Caroline Stremnitzer¹, Katie Matthews¹, Michael Fisher¹, William Windsor¹, James Blinn¹, Ellen M. Ginzler³ and Jefferson Tilley¹, ¹Innovimmune Biotherapeutics, Brooklyn, NY, ²SUNY-Downstate Medical Center, Brooklyn, NY, ³Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY
Background/Purpose: T helper 17 [TH17] cells and its production of TH17 cytokines IL-17A and IL-17F play a critical role in the pathogenesis of RA and…
Abstract Number: 2411 • 2014 ACR/ARHP Annual Meeting
Assessing Treatment Durability of Infliximab in the Management of Psoriatic Arthritis and Rheumatoid Arthritis Patients in a Canadian Setting
John Kelsall¹, Algis Jovaisas², Proton Rahman³, Dalton Sholter⁴, Michael Starr⁵, William Bensen⁶, Maqbool Sheriff⁷, Wojciech Olszynski⁸, Michel Zummer⁹, Rafat Faraawi¹⁰, Andrew Chow¹¹, Suneil Kapur¹², Emmanouil Rampakakis¹³, John S. Sampalis¹³, Francois Nantel¹⁴, Susan Otawa¹⁵, May Shawi¹⁴ and Allen J Lehman¹⁵, ¹The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ²194 Main Street, University of Ottawa, Ottawa, ON, Canada, ³Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁶St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸University of Saskatchewan, Saskatoon, SK, Canada, ⁹Université de Montréal, Montreal, QC, Canada, ¹⁰Medicine, McMaster University, Hamilton, ON, Canada, ¹¹McMaster University, Hamilton and Credit Valley Hospital, Mississauga, ON, Canada, ¹²Rheumatology, University of Ottawa, Ottawa, ON, Canada, ¹³JSS Medical Research, Montreal, QC, Canada, ¹⁴Janssen Inc., Toronto, ON, Canada, ¹⁵Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. The…
Abstract Number: 2037 • 2014 ACR/ARHP Annual Meeting
Incidence and Prevalence of Myasthenia Gravis in Rheumatoid Arthritis Patients with and without Treatment Compared with the General Population
Neil Accortt¹, Mary Anthony¹, Jennifer Schenfeld², Travis Wheeling², Anna Hassebroek², Cynthia O'Malley¹ and Michael Sprafka¹, ¹Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ²Docs Global, Inc, North Wales, PA
Background/Purpose: There is a dearth of information on the incidence rate of myasthenia gravis (MG) in the US and specifically among rheumatoid arthritis (RA) patients. …
Abstract Number: 2034 • 2014 ACR/ARHP Annual Meeting
A Treat-to-Target Strategy Preserves Work Capacity in Early Rheumatoid Arthritis (RA)
Mihir D. Wechalekar¹, Steve Quinn², Susan Lester³, Ella Shanahan⁴, Robert Metcalf⁵, E. Michael Shanahan⁶ and Susanna Proudman^4,7, ¹Flinders University School of Medicine, Adelaide, Australia, ²Flinders Clinical Effectiveness, Flinders University, Adelaide, Australia, ³Rheumatology Unit, Queen Elizabeth Hospital, Woodville South, Australia, ⁴University of Adelaide, Discipline of Medicine, Adelaide, Australia, ⁵University of Adelaide, Adelaide, Australia, ⁶Rheumatology, Flinders University, Bedford Park, South Australia, Australia, ⁷Department of Rheumatology, Royal Adelaide Hospital, SA, Australia
Background/Purpose Historical data (1)indicate a third of patients with RA are unable to work within the first 5 years of diagnosis. Our aim was to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].